Terms: = Leukemia AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Treatment
191 results:
1. Key candidate genes and pathways in T lymphoblastic leukemia/lymphoma identified by bioinformatics and serological analyses.
Ren Y; Liang H; Huang Y; Miao Y; Li R; Qiang J; Wu L; Qi J; Li Y; Xia Y; Huang L; Wang S; Kong X; Zhou Y; Zhang Q; Zhu G
Front Immunol; 2024; 15():1341255. PubMed ID: 38464517
[TBL] [Abstract] [Full Text] [Related]
2. Saracatinib prompts hemin-induced K562 erythroid differentiation but suppresses erythropoiesis of hematopoietic stem cells.
Ding L; Chen D; Li Y; Xie Y; Sun X; Wang D
Hum Cell; 2024 May; 37(3):648-665. PubMed ID: 38388899
[TBL] [Abstract] [Full Text] [Related]
3. Pilot study on the effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on body composition in children with acute lymphoblastic leukemia: randomized clinical trial.
Barbosa-Cortés L; Martínez-Vieyra X; Mejía-Aranguré JM; López-Alarcón M; Martin-Trejo J; Delgadillo-Portillo S; Guzmán-Castro B; Delgadillo-Portillo J; Atilano-Miguel S; Rodríguez-Cruz M; Maldonado-Hernández J; Añoveros-Barrera A; Solís-Labastida KA; Espinoza-Hernández L; Nuñez-Villegas NN; Jiménez-Hernández E; Bautista-Martínez BA; Juárez-Moya A; Hernández-Piñón Z; Pérez-Casillas RX
Clin Nutr; 2023 Sep; 42(9):1759-1769. PubMed ID: 37549598
[TBL] [Abstract] [Full Text] [Related]
4. Heterogeneity in leukemia cells that escape drug-induced senescence-like state.
Miller D; Kerkhofs K; Abbas-Aghababazadeh F; Madahar SS; Minden MD; Hébert J; Haibe-Kains B; Bayfield MA; Benchimol S
Cell Death Dis; 2023 Aug; 14(8):503. PubMed ID: 37543610
[TBL] [Abstract] [Full Text] [Related]
5. A novel stemness classification in acute myeloid leukemia by the stemness index and the identification of cancer stem cell-related biomarkers.
Huang Y; Zhang Z; Sui M; Li Y; Hu Y; Zhang H; Zhang F
Front Immunol; 2023; 14():1202825. PubMed ID: 37409118
[TBL] [Abstract] [Full Text] [Related]
6. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
[TBL] [Abstract] [Full Text] [Related]
7. Effect of long-chain omega-3 polyunsaturated fatty acids on cardiometabolic factors in children with acute lymphoblastic leukemia undergoing treatment: a secondary analysis of a randomized controlled trial.
Barbosa-Cortes L; Atilano-Miguel S; Martin-Trejo JA; Jiménez-Aguayo E; Martínez-Becerril FI; López-Alarcón M; Mejía Aranguré JM; Maldonado-Hernández J; Delgadillo-Portillo S; Guzmán-Castro B; Delgadillo-Portillo J; Añoveros-Barrera A; Solis-Labastida KA; Bautista-Martinez BA; Juárez-Moya A; Hernández-Piñón Z; Espinoza Hernández LE; Núñez-Villegas NN; Jiménez-Hernández E; Pérez-Casillas RX
Front Endocrinol (Lausanne); 2023; 14():1120364. PubMed ID: 37124732
[TBL] [Abstract] [Full Text] [Related]
8. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the timp1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract] [Full Text] [Related]
9. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML.
Gyan E; Pigneux A; Hunault M; Peterlin P; Carré M; Bay JO; Bonmati C; Gallego-Hernanz MP; Lioure B; Bertrand P; Vallet N; Ternant D; Darrouzain F; Picou F; Béné MC; Récher C; Hérault O
Sci Rep; 2022 Jun; 12(1):9748. PubMed ID: 35697729
[TBL] [Abstract] [Full Text] [Related]
10. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract] [Full Text] [Related]
11. New Approaches to Myelodysplastic Syndrome treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract] [Full Text] [Related]
12. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Mitchell S; Zhang P; Cannon M; Beaver L; Lehman A; Harrington B; Sampath D; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jun; 14(1):101. PubMed ID: 34187548
[TBL] [Abstract] [Full Text] [Related]
13. Circulating MMP-7 and VEGF as potential predictive biomarkers for recurrent implantation failures.
Benkhalifa M; Zidi W; Bahri H; Mahjoub S; Boudhraa K; Sanhaji H; Khorsi-Cauet H; Feki M; Benkhalifa M; Allal-Elasmi M
Zygote; 2021 Oct; 29(5):365-371. PubMed ID: 33736747
[TBL] [Abstract] [Full Text] [Related]
14. Safety of Eicosapentaenoic Acid in Cancer treatment: Effect on Cancer Cells and Chemotherapy in Vitro.
Aktaş S; Ercetin P; Altun Z; Kantar M; Olgun N
Nutr Cancer; 2021; 73(4):568-571. PubMed ID: 33678115
[TBL] [Abstract] [Full Text] [Related]
15. [A monocentric study on the management of patients with myelodysplastic syndromes in Morocco].
Maaroufi HE; Ababou M; Hammani A; Ahchouch S; Jennane S; Mahtat M; Mikdmae M; Messaoudi N; Doghmi K
Pan Afr Med J; 2020; 37():300. PubMed ID: 33654519
[TBL] [Abstract] [Full Text] [Related]
16. Lenalidomide-epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.
List AF; Sun Z; Verma A; Bennett JM; Komrokji RS; McGraw K; Maciejewski J; Altman JK; Cheema PS; Claxton DF; Luger SM; Mattison RJ; Wassenaar TR; Artz AS; Schiffer CA; Litzow MR; Tallman MS
J Clin Oncol; 2021 Mar; 39(9):1001-1009. PubMed ID: 33439748
[TBL] [Abstract] [Full Text] [Related]
17. A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells.
Nifant'ev I; Siniavin A; Karamov E; Kosarev M; Kovalchuk S; Turgiev A; Nametkin S; Bagrov V; Tavtorkin A; Ivchenko P
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396968
[TBL] [Abstract] [Full Text] [Related]
18. Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Cesini L; Frieri C; Baratè C; Sorà F; Bonifacio M; Cerrano M; Cagnetta A; Elena C; Aprile L; Sgherza N; Trawinska M; Gozzini A; Capodanno I; Crugnola M; Carmosino I; Scalzulli E; Ricci F; Bocchia M; Bergamaschi M; Aguzzi C; Sica S; Galimberti S; Breccia M; Luciano L; Latagliata R
Eur J Haematol; 2020 Sep; 105(3):286-291. PubMed ID: 32365249
[TBL] [Abstract] [Full Text] [Related]
19. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
[TBL] [Abstract] [Full Text] [Related]
20. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
Balleari E; Filiberti RA; Salvetti C; Allione B; Angelucci E; Bruzzone M; Calzamiglia T; Cavaliere M; Cavalleri M; Cilloni D; Clavio M; Crisà E; Da Col A; Danise P; Pilo F; Ferrero D; Finelli C; Gioia D; Lemoli RM; Masiera E; Messa E; Miglino M; Musto P; Natalie Oliva E; Poloni A; Salvi F; Sanna A; Scudeletti M; Tassara R; Santini V
Cancer Med; 2019 Dec; 8(18):7567-7576. PubMed ID: 31657156
[TBL] [Abstract] [Full Text] [Related]
[Next]
